- Conditions
- Prostate Cancer Metastatic
- Interventions
- ARV-110
- Drug
- Lead sponsor
- Arvinas Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 54
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 51 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1585–1608
of 85,906
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Squamous Cell Lung Carcinoma, Stage IV Large Cell Lung Carcinoma, Stage IV Lung Adenocarcinoma, Stage IV Squamous Cell Lung Carcinoma
- Interventions
- Bevacizumab, Carboplatin, Cetuximab, Laboratory Biomarker Analysis, Paclitaxel
- Biological · Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2022
- U.S. locations
- 797
- States / cities
- Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 473 more
- Conditions
- Intermittent Claudication
- Interventions
- K-134, Cilostazol 100 mg BID, Placebo
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 387 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 30
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Beverly Hills, California + 27 more
- Conditions
- Seasonal Allergic Rhinitis, SAR
- Interventions
- BDP HFA, Placebo nasal aerosol
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 715 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 45
- States / cities
- Oxford, Alabama • Bell, California • Costa Mesa, California + 40 more
- Conditions
- Diabetic Neuropathy, Painful
- Interventions
- AGN 203818, placebo capsule
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Atypical Squamous Cells of Undetermined Significance, Cervical Cancer, High-grade Squamous Intraepithelial Lesion, Low-grade Squamous Intraepithelial Lesion
- Interventions
- HspE7, placebo, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Autism Spectrum Disorder
- Interventions
- Minocycline
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 35 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Human Immunodeficiency Virus (HIV) Infection
- Interventions
- Etravirine
- Drug
- Lead sponsor
- Janssen R&D Ireland
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Beverly Hills, California • North Hollywood, California + 6 more
- Conditions
- Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Vitamin d Deficiency, Secondary Hyperparathyroidism
- Interventions
- CTAP101, Placebo
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Greenville, South Carolina
- Conditions
- Glioblastoma, Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme
- Interventions
- Unpulsed DCs, Td, Human CMV pp65-LAMP mRNA-pulsed autologous DCs, 111In-labeled DCs, Temozolomide, Saline, Basiliximab
- Biological · Drug
- Lead sponsor
- Mustafa Khasraw, MBChB, MD, FRCP, FRACP
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
- Interventions
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Diagnostic Imaging Testing, Inotuzumab Ozogamicin, Leucovorin Calcium, Lumbar Puncture, Methotrexate, Pegaspargase, Vincristine
- Drug · Procedure · Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 156
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 127 more
- Conditions
- Ocular Hypertension, Glaucoma
- Interventions
- latanoprost 0.005%, fixed combination latanoprost-timolol, timolol 0.5%
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 1999
- U.S. locations
- 53
- States / cities
- Anaheim, California • Sacramento, California • San Francisco, California + 39 more
- Conditions
- Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)
- Interventions
- Volrustomig, Cisplatin, Carboplatin, Paclitaxel, 5-FU
- Biological · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 257 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Baltimore, Maryland • New York, New York + 3 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- pramlintide acetate
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 25
- States / cities
- Tempe, Arizona • Concord, California • Fresno, California + 22 more
- Conditions
- Healthy, Fragile X Syndrome
- Interventions
- Follicle Aspiration
- Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 116 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- HIV Seropositivity
- Interventions
- Placebo, Rouvastatin calcium
- Drug
- Lead sponsor
- Alison Morris
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 3
- States / cities
- Los Angeles, California • San Francisco, California • Pittsburgh, Pennsylvania
- Conditions
- Symptomatic Uterine Fibroids
- Interventions
- Global Fibroid Ablation (GFA), Abdominal or Laparoscopic Myomectomy, Uterine Artery Embolization (UAE)
- Procedure
- Lead sponsor
- Acessa Health, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 9
- States / cities
- Santa Monica, California • Walnut Creek, California • Augusta, Georgia + 6 more
- Conditions
- Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Rheumatoid Arthritis
- Interventions
- NKX019, Fludarabine, Cyclophosphamide
- Drug
- Lead sponsor
- Nkarta, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Plantation, Florida • Tampa, Florida + 9 more
- Conditions
- Gestational Diabetes, Pregnancy, High Risk, Overweight and Obesity
- Interventions
- Intensive glycemic targets, Standard glycemic targets
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 828 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Indianapolis, Indiana • Norman, Oklahoma + 2 more
- Conditions
- Chronic Rhinosinusitis (Diagnosis)
- Interventions
- Comparison of medication administration for pain control
- Other
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- IgA Monoclonal Gammopathy, IgG Monoclonal Gammopathy, IgM Monoclonal Gammopathy, Light Chain Deposition Disease, Monoclonal Gammopathy, Smoldering Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinemia, Gammopathy, Monoclonal, Gammopathy Igg
- Interventions
- Rifaximin
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Postoperative Pain
- Interventions
- Nicotine (drug)
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV Infections
- Interventions
- PennVax B, IL-12, IL-15
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 4 more
- Conditions
- Solid Tumors
- Interventions
- ONT-10
- Biological
- Lead sponsor
- Cascadian Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Dallas, Texas • Tacoma, Washington